Domagoj Vucic

11PUBLICATIONS
54CO-AUTHORS
Molecular targetsProteomics and intermolecular interactions (excl. medical proteomics)Immunogenetics (incl. genetic immunology)Cell development, proliferation and deathMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Oct 25, 2024
RIP1 inhibition protects retinal ganglion cells in glaucoma models of ocular injury.

Bo Kyoung Kim, Tatiana Goncharov, Sébastien A Archaimbault

|Dec 20, 2023
Inhibition of RIP1 improves immune reconstitution and reduces GVHD mortality while preserving graft-versus-leukemia effects.

Mariano Prado-Acosta, Seihwan Jeong, Alberto Utrero-Rico

|Oct 04, 2023
cIAPs control RIPK1 kinase activity-dependent and -independent cell death and tissue inflammation.

Fabian Schorn, J Paul Werthenbach, Mattes Hoffmann

|Aug 19, 2023
A phase I, randomized, ascending-dose study to assess safety, pharmacokinetics, and activity of GDC-8264, a RIP1 inhibitor, in healthy volunteers.

Nicholas S Jones, Smita Kshirsagar, Vishnu Mohanan

|May 06, 2022
RIP1 post-translational modifications.

Eugene Varfolomeev, Domagoj Vucic

Pageof 2